Title: Methods, Compositions, and Drug-delivery Systems for Intraocular Delivery of siRNA Molecules
Patent Number: 8,586,556
Filed: Dec. 21, 2009
Lead Inventor: Robert Lyons, Allergan
The patent, its abstract states, claims "biocompatible intraocular drug-delivery systems in the form of an implant for intraocular administration of siRNA molecules. The drug-delivery systems may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma, and proliferative vitreoretinopathy, among others."
Title: Therapy of p53 Mutant Colon Adenocarcinoma, Breast Cancer, and Lung Cancer
Patent Number: 8,586,557
Filed: March 25, 2010
Lead Inventor: Ygal Haupt, Peter MacCallum Cancer Institute
The invention, the patent's abstract states, provides "a method for treating a hyperproliferative disorder characterized by expression of a mutant form of p53 in a subject … [by] administering to the subject a therapeutically effective amount of an agent which inhibits promyelocytic leukemia protein."
That agent, the patent notes, can be an siRNA or an shRNA.
Patent Number: 8,586,725
Filed: Feb. 16, 2007
Lead Inventor: Jordan Cummins, Johns Hopkins University
"We have developed an experimental approach called miRNA serial analysis of gene expression — miRAGE — and used it to perform the largest experimental analysis of human miRNAs to date," the patent's abstract states. "Sequence analysis of 273,966 small RNA tags from human colorectal cells allowed us to identify 200 known mature miRNAs, 133 novel miRNA candidates, and 112 previously uncharacterized miRNA* forms. To aid in the evaluation of candidate miRNAs, we disrupted the Dicer locus in three human colorectal cancer cell lines and examined known and novel miRNAs in these cells. The miRNAs are useful to diagnose and treat cancers."
Title: Tissue-specific microRNAs and Compositions and Uses Thereof
Patent Number: 8,586,726
Filed: Jan. 15, 2010
Lead Inventor: Andrea Califano, Columbia University
"The invention provides for isolated nucleic acid sequences of newly discovered microRNAs that have been identified to exist in normal human B cells and/or in tumor-related human B cells using an integrated bioinformatics method and pipeline," the patent's abstract states.
Title: Synthetic Mimics of miR-34
Patent Number: 8,586,727
Filed: Feb. 3, 2012
Lead Inventor: Kevin Kelnar, Mirna Therapeutics
The invention, the patent's abstract states, comprises "miR-34 mimics, including miR-34a and miR-34c mimics. In some embodiments, there are double-stranded RNA molecules with modified nucleotides having an active strand with a miR-34a sequence and a complementary passenger strand. In additional embodiments, there are double-stranded RNA molecules with modified nucleotides having an active strand with a miR-34c sequence and a complementary passenger strand."